Posts

Posted on

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) — All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”

The Company stated that, on June 5, AIFA Chairman and Chief Executive Officer James Li met at Morgan Stanley’s Hong Kong headquarters with senior executives of Morgan Stanley and a delegation from the Lingshui government of Hainan Province. The parties held in-depth discussions regarding AIFA’s proposed leadership role in advancing the construction of silicon photonics compute and storage infrastructure in Hainan and, together with Southeast Asian fiber connectivity resources, building the AIFA Digital Industrial Park.

I. Planning the Overall Layout of the AIFA Digital Industrial Park Around the Hainan Project and Cross-Border Optical Network Synergies

The Company believes that, as global demand for AI computing, cross-border data flows, cloud services, data centers, and digital infrastructure continues to grow, competition among high-value digital infrastructure platforms is evolving from isolated compute capacity competition toward integrated capabilities across “compute + storage + optical transmission + cross-border connectivity + application scenarios.”

Based on this view, and with strong support from the Hainan government, the Company is seeking to upgrade the Hainan project from a standalone compute center plan into a broader AIFA Digital Industrial Park centered on silicon photonics compute, distributed storage, cross-border fiber connectivity, international data transmission, and future AI application incubation.

As previously disclosed, the Hainan AIFA Silicon Photonics Supercomputing Center is proposed to be located on the Company’s own industrial land parcel in Qingshui Bay, Lingshui, Hainan Free Trade Port, leveraging the area’s strategic position as an international submarine cable landing hub to build an offshore silicon photonics supercomputing hub serving global markets. The Company has also previously disclosed that the project is intended to focus on silicon photonics interconnect and optical computing technologies, with business lines including high-end compute leasing, advanced distributed storage, cross-border compute orchestration, AI token output services, and full-cycle value-added services.

The Company believes that, if the Hainan silicon photonics compute center can be effectively integrated in the future with HyalRoute’s Southeast Asian fiber backbone networks, cross-border optical transmission capabilities, and submarine cable resources, it may create a more complete infrastructure closed loop of “optical compute + optical transmission + optical storage,” further enhancing the Company’s differentiated positioning within the global digital infrastructure value chain.

II. Discussions With the Lingshui Government Delegation Regarding Project Implementation and Policy Support

The Company stated that, during the Hong Kong meeting, AIFA management and the Lingshui government delegation of Hainan Province focused on discussions regarding the overall planning of the Hainan AIFA Digital Industrial Park, the project implementation pathway, coordination of supporting resources, areas of potential policy support, and subsequent implementation arrangements.

The Company believes that the Hainan Free Trade Port has unique advantages in areas such as cross-border data pilot programs, international communications channels, tax policies, importation of advanced equipment, and digital industry development. As previously disclosed, the Hainan AIFA Silicon Photonics Supercomputing Center may benefit from a number of Hainan Free Trade Port policy advantages, including offshore tax incentives, duty-free importation of advanced equipment, cross-border data pilot policies, and dedicated international communications channels, which may help reduce project construction and operating costs.

The Company is continuing to communicate with the relevant parties in an effort to obtain active support from the Lingshui government of Hainan Province for project planning, industrial deployment, and subsequent construction. The specific content of any policy support, cooperation model, and implementation arrangements remain subject to further discussions, project progress, and completion of applicable approval procedures.

During the strategic meeting, AIFA also discussed project financing arrangements with Morgan Stanley executives. Under the current preliminary plan, the Company intends to coordinate financing support through multiple financial institutions, including Morgan Stanley, to support the infrastructure construction of the Hainan AIFA Digital Industrial Park.

III. Government Approval Processes Relating to the HyalRoute Project Are Also Underway

The Company further stated that, in addition to the planning of the Hainan AIFA Digital Industrial Park, the governmental approval processes and procedural advancement relating to the Company’s previously announced acquisition of a controlling interest in HyalRoute are also progressing in parallel.

As previously disclosed, HyalRoute owns a pan-ASEAN fiber-optic network, AAE-1 international submarine cable resources, and related cross-border optical transmission capabilities, and the Company views the transaction as an important milestone in its transformation into an AI infrastructure platform with optical technologies at its core. The Company believes that, if the transaction and related approval procedures proceed smoothly, HyalRoute’s fiber backbone networks, cross-border transmission capabilities, submarine cable resources, and regional network operating capabilities will be highly complementary to the Hainan AIFA Silicon Photonics Supercomputing Center.

The Company reminds investors that, with respect to the HyalRoute transaction, the Company has signed equity acquisition agreements with the relevant HyalRoute shareholders; however, those agreements remain subject to agreed closing conditions, regulatory approvals, governance arrangements, and other customary conditions before they can become effective and close. The Company will disclose updates regarding the approval and closing process as appropriate based on subsequent developments.

With respect to HyalRoute itself, the Company is currently engaging with relevant shareholders and the Company’s management regarding post-closing management arrangements following completion of the equity transfer. The Company is also, through outside counsel, requesting that the relevant shareholders involved in the transaction provide additional information and supplemental materials regarding the target company. After completion of the relevant share transfers, the Company expects that investment banks, auditors, and professional advisors will conduct further substantive and detailed due diligence on HyalRoute. At present, certain information available to the Company concerning HyalRoute is based primarily on information provided and communicated by the relevant shareholders.

The transaction will not become substantively effective unless and until all necessary regulatory approvals have been obtained, including approvals from the relevant authorities in China, the United States, and other applicable jurisdictions. The Company also hopes that HyalRoute’s other state-owned shareholders, creditors and debt counterparties, and management team will maintain active and constructive communication with the Company in order to help advance the relevant work in a steady manner.

IV. M&A Progress in Related AI Application Areas

The Company is also evaluating multiple M&A opportunities in AI application sectors, including AI education, AI Poker, and AI drones, as well as related hardware and software projects, and will make disclosures as appropriate based on project progress.

V. Board Reorganization

To better align with the Company’s strategic transformation needs, the Company plans in the near term to advance a reorganization of its Board and an optimization of management, with the goal of introducing professionals more closely aligned with the Company’s new strategic direction and strengthening the Board’s and management team’s capabilities in areas such as AI applications, AI infrastructure, and optical communications, thereby providing stronger organizational support for future strategic execution.

Management Commentary

AIFA Chairman and Chief Executive Officer James Li stated:

“Through completion of the Company’s rebranding and the continued advancement of related acquisition transactions, the Company is undergoing a comprehensive transformation into a future technology platform driven by two core engines: an ‘AI infrastructure network’ and an ‘AI application services matrix.’ Around this strategic direction, the Company is actively screening, evaluating, and advancing multiple potential projects, and will make disclosures as appropriate based on the actual progress of relevant transactions and projects.

We will continue to advance related project planning, financing arrangements, and approval processes in a prudent, compliant, and disciplined manner, while remaining committed to creating long-term value for our shareholders.”

About All In FutureTech Alliance

All In FutureTech Alliance Inc. (Nasdaq: AIFA), formerly known as Allied Gaming & Entertainment Inc, is a growth-oriented company undergoing a strategic transformation from a global experiential entertainment business into an AI-focused digital infrastructure platform. The Company is pursuing opportunities in artificial intelligence infrastructure, silicon photonics-enabled compute, cross-border fiber-optical network transmission, digital infrastructure services, and technology-enabled growth initiatives. Through its proposed AIFA strategic platform, AIFA aims to build an integrated ecosystem combining AI compute capacity, fiber-optic network infrastructure, AI education and AI applications to support long-term value creation.

Forward-Looking Statements

This press release includes forward-looking statements within the safe harbor provisions provided under federal securities laws, including under the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. Important factors that may affect actual results include, among others, the Company’s ability to execute its growth strategy; the outcome of the Nasdaq hearings; market conditions; regulatory changes; operational challenges; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on May 22, 2026, and in subsequent filings with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from the Company’s expectations in any forward-looking statement. Readers are cautioned not to place undue reliance upon any forward-looking statements, including but not limited to the Company’s expectation with respect to the effect of the Reverse Stock Split. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contact:

Investor Relations: [email protected] 



Posted on

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

PR Newswire

  • Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early
  • Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention
  • Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1

ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ — Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association’s (ADA) June 2026 86th Scientific Sessions show sharp increases in DKA-related hospitalizations across all age groups nationwide. The data reinforces that while diabetes technology has advanced significantly, there are opportunities to better detect rising ketones before DKA develops.

Diabetic Ketoacidosis: Often Misunderstood and Difficult to Recognize

DKA develops in people with diabetes when the body does not have enough insulin and begins breaking down fat for energy, causing ketones to rise to dangerous levels in the blood.2 While traditionally associated with Type 1 diabetes, DKA is increasingly affecting people with Type 2 diabetes. The American Diabetes Association notes that high ketone levels can escalate to DKA within hours and, if left untreated, can lead to coma or death.2 Many people living with diabetes aren’t familiar with DKA or its symptoms, despite clinical guidance recommending ketone testing during periods of elevated glucose, making it a challenge to detect early.

New DKA Data from Abbott Presented at ADA’s Scientific Sessions

At the ADA’s Scientific Sessions, Abbott presented findings from multiple studies analyzing hospitalization, admission diagnosis and insurance claims data to better understand how DKA may be challenging to identify, its rising impact among young people, and a growing prevalence in adults with Type 2 diabetes.

  • DKA may be hard to identify early at hospital admissions: A study of over 100,000 people across the U.S. found that DKA can be difficult to recognize when a person first arrives at the hospital, as early symptoms – such as nausea, fatigue, or stomach pain – overlap with many common illnesses.3 A confirmed diagnosis of DKA depends on blood tests that measure blood sugar, blood pH and/or bicarbonate levels, and ketones, which may not be immediately available at admission.2 These delays highlight the need for approaches to recognize DKA earlier to provide timely care.
  • Better awareness of DKA may help curb hospitalizations: A second study of over 200,000 people showed that between 2017-2024, DKA hospitalization rates among people with Type 1 diabetes increased approximately 24%, rising from 50 to 62 cases per 1,000 individuals. The increase was more pronounced in children than adults.4 Most DKA events led to hospitalization for both children and adults, while severe hypoglycemia rates stayed low and stable, likely due to greater recognition of hypoglycemia and less awareness of DKA risk.4
  • Reducing DKA hospitalizations may improve health outcomes across all ages: One analysis of close to 40,000 pediatric hospitalizations showed DKA now drives nearly 60% of all diabetes-related hospitalizations among youth with Type 1 or Type 2 diabetes.1 Most U.S. hospitalizations among children with diabetes are related to DKA, with the majority requiring inpatient care lasting up to one week and costing up to $38,000 per stay.1 Findings from a separate study with data from millions of people indicate DKA is likely underreported in adults with Type 2 diabetes, and when diagnosed after admission as a secondary condition, is associated with longer hospital stays, higher costs, and increased rates of death.5

“These findings from Abbott show that diabetic ketoacidosis remains a growing challenge to identify, as DKA can develop quickly and mimic common illnesses,” said Kurt Midyett, M.D., pediatric endocrinologist at Saint Luke’s Endocrinology Specialists in Kansas City, Mo. “When early symptoms are misattributed, delays in diagnosis are common and often result in lengthy and costly hospitalization. This data underscores the importance of addressing gaps in recognition to help detect rising ketones before DKA develops.”

The Role of Ketone Monitoring in Diabetes Care

Continuous glucose monitors (CGMs) play an essential role in helping people manage their diabetes by providing real-time glucose insights. However, they do not currently measure ketones and DKA can still develop even when glucose levels appear stable.6 Insights from adults living with Type 1 diabetes show that while some people understand the importance of monitoring ketones, testing is often underused. Rising ketones can progress to DKA within hours, so earlier visibility has the potential to prompt action sooner and reduce risk.6

“These new data make clear that preventing diabetic ketoacidosis starts with recognizing risk earlier,” said Mahmood Kazemi, M.D., chief medical officer for Abbott’s diabetes care business. “DKA remains one of the most preventable emergencies in diabetes care, yet too many people still miss early warning signs when ketones levels begin to rise. These findings underscore the need for better ways to recognize risk sooner and help reduce avoidable hospitalizations.”

As an alternative to existing ketone monitoring options, Abbott has developed dual glucose-ketone sensing technology, which combines continuous glucose and ketone monitoring in a single sensor designed to support both daily diabetes management and help to detect rising ketone levels for people living with diabetes. Abbott announced CE Mark for the systems, called Libre Duo and Libre Duo 10 Day, in May 2026. The company has also filed a regulatory submission with the U.S. Food & Drug Administration (FDA). Libre Duo and Libre Duo 10 Day systems are not yet cleared by the FDA or available for sale in the United States.

Frequently Asked Questions

What is diabetic ketoacidosis?

Diabetic ketoacidosis (DKA) occurs when the body doesn’t have enough insulin. To get energy, the body starts breaking down fat, which releases acids called ketones into the blood.  People in DKA can experience severe dehydration, dangerous changes to potassium and other electrolytes, and coma.  Without prompt treatment, DKA can lead to coma or death.

Can people use urine and blood ketone monitors to test ketones?

Urine and blood ketone monitors are available, but they only offer a snapshot in time and depend on individuals or caregivers recognizing symptoms and deciding to test. Many do not check ketones regularly or lack testing supplies, which can delay action. In a study published in the British Medical Journal Open Diabetes Research & Care, 64% of participants do not test for ketones at all, which can lead to rising ketones that may go unnoticed until a medical emergency develops.7

Can a continuous glucose monitor (CGM) provide information that helps prevent diabetic ketoacidosis?

A CGM, like the FreeStyle Libre 3 Plus sensor, can play an important role in diabetes management, but they are not designed to measure ketones. Because rising ketones are a key driver of diabetic ketoacidosis, relying on glucose data alone may not always provide an early warning before diabetic ketoacidosis (DKA) develops. Abbott has developed a dual glucose-ketone sensing technology in the U.S. that is pending FDA clearance.

About Libre:

Abbott continues to pioneer groundbreaking technology to support people living with diabetes. The company revolutionized diabetes care more than 10 years ago with its world-leading Libre continuous glucose monitoring portfolio8, which today is used by more than 8 million people across over 60 countries. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries.8

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.

Important Safety Information: FreeStyle Libre 3 system is for prescription only, for Important Safety Information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

1 Sherr et al. Burden Of Diabetic Ketoacidosis Among Youth With Diabetes: A Hospital Claims Analysis.
2 American Diabetes Association. “Planning for Sick Days.” Accessed February 6, 2026. https://diabetes.org/getting-sick-with-diabetes/sick-days. 
3 Miller et al. Characterizing the Clinical Presentation of Diabetic Ketoacidosis Hospitalizations in People with Diabetes using Admitting Diagnoses. 
4 Trends in the Prevalence of Diabetic Ketoacidosis and Severe Hypoglycemia in Type 1 Diabetes. 
5 Galindo et al. Mortality And Costs of Diabetic Ketoacidosis Hospitalizations in People with Type 2 Diabetes: Differences Between Primary Vs. Secondary Diagnosis.
6 Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/
7 Hepprich, M., Roser, P., Stiebitz, S., Felix, B., Schultes, B., Schmitz, D., Rutishauser, J., Schubert, S., Aberle, J., & Rudofsky, G. (2023). Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey. BMJ open diabetes research & care, 11(6), e003662. https://doi.org/10.1136/bmjdrc-2023-003662 
8 Data on File, Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer.

Cision View original content:https://www.prnewswire.com/news-releases/new-abbott-data-show-many-people-with-diabetes-may-not-recognize-symptoms-of-diabetic-ketoacidosis-302793024.html

SOURCE Abbott

Posted on

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

  • Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy
  • VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide
  • Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA).

The objectives for the Phase 2 studies were to identify the right doses for Phase 3 and to test escalation schemes. Across both weekly and monthly dosing in participants with obesity or overweight, with and without type 2 diabetes, the data from the Phase 2b VESPER-1, 2 and 3 studies:

  • provide proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide that can deliver competitive weight loss;

  • show favorable tolerability for berobenatide, including low gastrointestinal (GI) adverse events and discontinuations despite rapid dose escalation and no allowed step-down; and

  • highlight the potential for monthly delivery in a patient-friendly presentation with a very low 0.5 mL injection volume that provides convenience and scalability advantages.

The first clinical experience with the top weekly dose for berobenatide is being presented today for the first time. Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9%* with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide. VESPER-1 is evaluating once-weekly berobenatide in adults with obesity or overweight, including Part B to assess the durability of weight loss and the impact of transitioning from once-weekly to less frequent dosing regimens, including once-monthly.

“In Phase 2b studies, berobenatide delivered continuous, uninterrupted weight loss at all doses selected for Phase 3, while preserving a tolerable profile as people transitioned from a weekly to a monthly maintenance dose,” said Jim List, MD, PhD, Chief Internal Medicine Officer, Pfizer. “These data highlight the potential for berobenatide to be the first approved monthly GLP-1 RA peptide and support our extensive Phase 3 program that includes 10 studies for chronic weight management and obesity-related comorbidities. With berobenatide as a potential foundational metabolic medicine, both as a single agent and as a combination backbone, Pfizer is advancing a differentiated pipeline with multiple mechanisms and modalities designed to meet the many needs of people living with obesity and related conditions.”

Detailed results from the previously reported Phase 2b VESPER-3 study are also being presented today, which is evaluating monthly maintenance dosing of berobenatide in adults with obesity or overweight without type 2 diabetes. In addition, data from the Phase 2b VESPER-2 study, which evaluated weekly dosing of berobenatide in adults with obesity or overweight and type 2 diabetes, showed dose dependent reductions from baseline were observed with berobenatide for both body weight and HbA1c. Of note, there was a 2.2%** reduction in HbA1c achieved with berobenatide 1.6 mg weekly at week 28 (on treatment [efficacy] estimand), compared to a reduction of 0.2% in the placebo group.

“Weight management is a lifelong commitment, and the barriers to staying on therapy long-term are just as important as the therapy itself,” said John B. Buse, MD, PhD, Professor of Medicine at the University of North Carolina School of Medicine, Chapel Hill. “The growing body of evidence shows berobenatide delivering meaningful weight loss with a well-tolerated profile following a switch from weekly to monthly dosing in Phase 2b studies. If approved, berobenatide has the potential to not only be effective, but practical and sustainable in real life.”

The VESPER-6 pivotal Phase 3 study investigating monthly maintenance dosing for berobenatide in adults with obesity or overweight is open for enrollment, as well as the SOLIS-1 Phase 2b study investigating weekly and monthly maintenance dosing of an ultra-long-acting amylin analog (PF’3945) as a monotherapy and in combination with berobenatide.

An investor slide presentation with more information about the VESPER clinical development program and the clinical trial results contained in this release will be available on Pfizer’s web site at 10:00 a.m. CT / 11:00 a.m. ET at www.pfizer.com/investors.

About Berobenatide and Pfizer’s Cardiometabolic Pipeline

Pfizer plans to advance 20+ trials for obesity and related comorbidities in 2026. This includes 10 ongoing and planned Phase 3 trials for berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide being studied for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea. The growing body of evidence supports advancing an extensive development program for berobenatide as a monotherapy and in combination with various Nutrient-Stimulated Hormone (NuSH) peptides including amylin analogs.

About the VESPER Clinical Development Program

The VESPER clinical development program is a comprehensive global program evaluating berobenatide across a range of patient populations and dosing regimens in chronic weight management.

Phase 2b VESPER studies include:

  • VESPER-1: A Phase 2b trial in adults with obesity or overweight evaluating once-weekly berobenatide, including a 32-week exploratory extension (Part B) assessing the durability of weight loss and the impact of transitioning from once-weekly to less frequent dosing regimens, including once-monthly administration. Part A was the initial 28-week double-blind placebo-controlled portion of the study.

  • VESPER-2: A Phase 2b randomized, double-blind, placebo-controlled trial evaluating once- weekly berobenatide in adults with obesity or overweight and type 2 diabetes, designed to assess weight loss, glycemic control and safety in this population.

  • VESPER-3 is an ongoing 64-week, randomized, double-blind, placebo-controlled study in participants with obesity or overweight without type 2 diabetes. The study is designed to evaluate weekly (QW) titration phase to monthly (QM) dosing of berobenatide in four different titration and QM dose arms, compared to placebo.

Phase 3 VESPER studies include:

  • VESPER-4 is an ongoing Phase 3 pivotal study investigating once-weekly berobenatide in adults with obesity or overweight and without type 2 diabetes.

  • VESPER-5 is an ongoing Phase 3 pivotal study investigating once-weekly berobenatide in adults with obesity or overweight and type 2 diabetes. A higher weekly dose of berobenatide (2.4 mg) is currently being evaluated in Phase 3.

  • VESPER-6 is a Phase 3 pivotal study investigating once-monthly berobenatide in adults with obesity or overweight. The study is now open for enrollment.

  • Seven additional planned Phase 3 studies of berobenatide are designed to target comorbidities and increase patient optionality and access.

About Obesity

Obesity is a growing global epidemic. In 2015, it was estimated that approximately 1.9 billioni people were living with obesity or considered overweight, and this number is expected to grow to more than 2.9 billion by 2030.ii Obesity is a complex metabolic disease, often defined in adults as having a body mass index (BMI) greater than or equal to 30.iii It is associated with more than 200 health conditions,iv contributing to significant chronic disease burden, shortened lifespans, and growing healthcare costs. Despite recent advances in care, for many patients, current therapies are not sufficient—whether due to limited efficacy, tolerability issues that impact adherence, co-morbidities that weight loss alone doesn’t address, or barriers to access and affordability. New waves of innovation that better meet the diverse needs of patients are critical to effectively address this epidemic.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice

The information contained in this release is as of June 6, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about berobenatide (PF’3944; previously called MET-097i), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and results and expectations from Phase 2b VESPER studies, including the VESPER-1 exploratory extension, VESPER-2, and VESPER-3, the potential of berobenatide to be the first approved monthly GLP-1 receptor agonist peptide, potential product profile and positioning, Pfizer’s investigational cardiometabolic pipeline, and anticipated clinical trial starts and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data, including the risk that analysis of longer term data does not match our expectations based on the data disclosed in this release; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities, including the population regulatory authorities deem relevant for regulatory decisions; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for berobenatide or any other product candidates for any potential indications; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether berobenatide or any such other product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of berobenatide or any such other product candidates; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

_________________

* Data are arithmetic means

** Least squares means calculated using a mixed model for repeated measures excluding protocol-defined intercurrent events (i.e., on-treatment estimand).

iWorld Obesity Atlas 2025

iiAmerican Medical Association

iii World Health Organization. Obesity and Overweight. Accessed June 9, 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

iv American Medical Association. Obesity. https://www.ama-assn.org/topics/obesity.

 

Media Contact: [email protected]

Investor Contact: [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Health Diabetes Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

  • STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types
  • EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings

ACTON, Mass.–(BUSINESS WIRE)–
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet’s technology today—it also fuels continued investment in breakthrough innovation designed to improve outcomes, reduce daily effort, and expand access to diabetes technology.

Results from the STRIVE pivotal trial and the EVOLUTION 3 feasibility study, presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, demonstrate meaningful improvements in glucose control for people with diabetes using Insulet’s future AID system — Omnipod 6 — and unique fully closed-loop (FCL) system for type 2 diabetes.*

“Omnipod 6 represents one of our biggest steps forward yet, with greater personalization and responsiveness to hyperglycemia, by delivering up to 50% more automated insulin, as shown in the STRIVE results,” said Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer at Insulet. “Our fully closed-loop system for type 2 diabetes is intentionally designed to unlock barriers to AID by managing mealtime insulin and simplifying workflows to expand clinic adoption. Strong results from EVOLUTION 3 bring us one big step closer to making fully closed-loop for type 2 diabetes a reality.”

Together, results from STRIVE and EVOLUTION 3 underscore Insulet’s continued commitment to building a future where managing diabetes is dramatically simpler. This progress aligns with the Company’s innovation philosophy: build technology that doesn’t just do more but demands less.

STRIVE Study Overview

The STRIVE pivotal trial was designed to evaluate the safety and efficacy of the next-generation Omnipod 6 algorithm.

The randomized, crossover study included 132 participants across the U.S., including 98 with type 1 diabetes and 34 with type 2 diabetes. The type 1 cohort spanned a broad age range, including 29 participants aged 2 to <6 years, 36 aged 6 to <14 years, and 33 aged 14–70 years. Baseline glycemia was near recommended targets, with mean HbA1c values of 6.9% and 7.3% for type 1 and type 2 diabetes, respectively.

Participants were randomized to use either the Omnipod 6 algorithm at the 100 mg/dL Target Glucose or the Omnipod 5 System at the 110 mg/dL Target Glucose for four weeks, followed by crossover to the alternate system for an additional four weeks. After the Crossover Phase, all participants entered a four-week or six-week Bolus Optional Phase to evaluate whether glycemic outcomes could be maintained with reduced user interaction, with a study goal of three or fewer boluses per day.

STRIVE Key Data Highlights

Enhanced glycemic performance, even with limited bolusing

The STRIVE study demonstrated clinically meaningful improvements in glycemic outcomes with Omnipod 6 during the Crossover Phase.

  • Improved time in tight range (70–140 mg/dL) with Omnipod 6 vs. Omnipod 5:

    • Type 1 diabetes (≥14 years): 54% vs. 47% (+7 pts)

    • Type 2 diabetes: 48% vs. 43% (+5 pts)

  • Improved time in range (70–180 mg/dL) with Omnipod 6 vs. Omnipod 5:

    • Type 1 diabetes (≥14 years): 77% vs. 73% (+4 pts)

    • Type 2 diabetes: 76% vs. 73% (+3 pts)

  • Maintained safety profile:

    • Time <54 mg/dL and <70 mg/dL were non-inferior

    • No instances of diabetic ketoacidosis (DKA) or severe hypoglycemia

The STRIVE study demonstrated strong glycemic performance even when users bolused less during the Bolus Optional Phase.

  • Strong time in range and time in tight range with fewer boluses:

    • Type 1 diabetes (≥14 years): 76% time in range and 54% time in tight range with 2.2 fewer boluses/day

    • Type 2 diabetes: 74% time in range and 46% time in tight range with 2.5 boluses per day

  • These findings suggest Omnipod 6 may be especially helpful for people with diabetes who do not always bolus. This will be further tested in the upcoming STRIVE 2 study, which will evaluate Omnipod 6 among people who bolus fewer than four times per day and are not meeting clinical targets for HbA1c.

EVOLUTION 3 Study Overview:

Insulet also shared results from EVOLUTION 3, the pre-pivotal study evaluating the safety and effectiveness of the Company’s breakthrough FCL system for adults with type 2 diabetes.

EVOLUTION 3 enrolled a demographically diverse cohort comprised of 36 participants (adults aged 18–75 years old) with type 2 diabetes using insulin with HbA1c<14%. Participants were intensively managed with basal-bolus therapy and had high baseline utilization of continuous glucose monitoring. Yet they still had high baseline HbA1c of 8.1%.

EVOLUTION 3 Key Data Highlights

Fully Closed-Loop for type 2 diabetes improved time in range and reduced daily insulin with no weight gain

  • Insulet’s FCL for type 2 diabetes delivered 64% time in range, a 12% improvement with low hypoglycemia (0.15%) in a diverse, intensively managed population.

  • Total daily insulin was reduced from 86U to 58U with no weight gain.

  • Participants also reported high satisfaction (86% satisfied or highly satisfied) and reduced burden with FCL.

This data is part of the broader clinical program used to support the development of the FCL AID system designed for people living with type 2 diabetes. The EVOLUTION 2 results were shared earlier this year at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), and Insulet recently announced the first enrollment of participants in EVOLVE, the randomized controlled pivotal trialsupporting a planned 2027 510(k) filing to the FDA and expected 2028 commercial launch. Building on this experience from FCL for type 2 diabetes, early clinical work is underway to advance the science for FCL for type 1 diabetes as well.

Sharing STRIVE and EVOLUTION 3 at ADA

The studies will be discussed at ADA this weekend, including on Sunday, June 7 from 10:15 – 11:00 AM CT in the Product Theater. Dr. Ly will be joined by Dr. Sufyan Hussain, MA, MB BChir, MRCP, PhD and Dr.Gregory Forlenza, MD, MS, for an Insulet sponsored presentation, The Omnipod Difference: Patient Centered Simplicity and Breakthrough Algorithm Performance.

* Insulet’s Omnipod 6 and FCL System for type 2 diabetes are investigational devices. Limited by federal (or United States) law to investigational use. These products have not been reviewed by the FDA or any other regulatory agency.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 18, 2026 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary materially from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Media:

Cristal Downing

Chief Corporate Affairs Officer

[email protected]

Investor Relations:

Clare Trachtman

Vice President, Investor Relations

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical General Health Health Diabetes Medical Devices Health Technology Clinical Trials

MEDIA:

Logo
Logo
Posted on

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Deep, dose-dependent B cell depletion observed in peripheral blood and tissue

Favorable safety profile with single target doses up to 30
µg as well as initial multi-dose regimen

Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan’s Immunology Day on June 10

CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, announced today that it will present initial clinical data from two ongoing Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The data will be presented today, June 6, at 10:15 am BST (Poster number POS1179).

“Following a single target dose of CLN-978, patients with refractory SLE and difficult-to-treat RA demonstrated clinical benefit, including remissions. These initial Phase 1 data demonstrate the deep and dose-dependent B cell depletion achievable with CLN-978 and reinforce our belief that it has strong potential as a disease-modifying treatment in multiple challenging-to-treat autoimmune conditions,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “But just as important, the emerging safety profile and subcutaneous administration support the potential to deliver substantial clinical benefit to patients in the outpatient, community-based care setting. With study of multi-dose regimens underway, we are focused on advancing CLN-978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients.”

“The data emerging from this program represent one of the most comprehensive and rigorous datasets generated to date across multiple indications and biomarkers, and help to inform further clinical development of this program as well as how these therapies may be ultimately used in clinical practice,” said Ricardo Grieshaber-Bouyer, MD, PhD, MHBA, Professor of Clinical Systems Immunology and Head of the Clinical Trials Unit at FAU Erlangen-Nuremberg, and global Principal Investigator for OUTRACE RA. “Patients with rheumatoid arthritis and systemic lupus erythematosus whose disease remains active despite exhausting multiple available therapies continue to have significant unmet need. In many patients, a single target dose of CLN-978 demonstrated rapid depletion of B cells not just in peripheral blood, but notably also clearance of CD19+ B cells in lymph node and synovial tissue. The encouraging safety profile and clear dose-dependent effects provide strong evidence of the underlying mechanism of action.”


Key Data Highlights

This presentation is based on data from 29 patients evaluated as of May 15, 2026, across various dose levels in the OUTRACE SLE and RA clinical trials.

  SLE (n=18) RA (n=11)
Dose levels investigated Safety PD Efficacy Safety PD Efficacy
Cohort 1 (D1: 10 µg) 3 3 3 1 1 1
Cohort 2 (D1: 10 µg, D8: 20 µg) 7 7 4 3 3 3
Cohort 3 (D1: 10 µg, D8: 30 µg) 7 6 6 3 3 3
Cohort 4 (D1: 10 µg, D8: 45 µg) 1 1 1 – – –
Cohort 5 (D1: 10 µg, D8/15/22: 20 µg) – – – 4 – –
Total patients 18 17 14 11 7 7

*PD=pharmacodynamics.

Based on timing of data cutoff, various data for certain patients were not yet available.

Clinical activity and biomarker findings in OUTRACE SLE

In the OUTRACE SLE trial, highlights of the data for patients treated with a single target dose include:

  • Among 14 patients with ≥4 weeks follow up, a ≥4-point reduction in hSLEDAI was observed in 10 patients (71%), with 5 achieving a DORIS remission
  • All lab markers of disease activity (anti-dsDNA, UPCR, C3 and C4) improved in patients with clinically significant abnormalities at baseline
  • Following a single target dose of CLN-978, peripheral B cell counts were reduced by >80% from baseline in 14 of 17 patients (82%), with dose-dependent recovery
    • Peripheral B cell depletion below the limit of quantification (BLOQ) was achieved in 7 of 14 patients (50%) treated at target doses ≥20 µg

Clinical activity and biomarker findings in OUTRACE RA

In the OUTRACE RA trial, highlights of the data for patients treated with a single target dose include:

  • In this heavily pretreated population, 6 of 7 patients (86%) had high baseline disease activity. Disease activity improved in 5 of 7 patients (71%), including a DAS28-ESR remission in 1 patient treated with a single 30 μg target dose
  • CLN-978 reduced RA autoantibody levels without impact on protective vaccine titers
  • Peripheral blood B cell depletion BLOQ was achieved in 4 of 6 patients (67%) treated at target doses ≥20 µg
  • Dose dependent B cell depletion was also observed in lymph node and synovial tissue

Safety Profile in Patients with SLE and RA

  • CLN-978 was well tolerated across the 10 μg, 20 μg and 30 μg target dose cohorts, including in patients who received 3 administrations of the 20 μg target dose in a multi-dose regimen
  • Most cytokine release syndrome (CRS) events were Grade 1 and occurred following the first dose (10 μg). A single case of Grade 3 CRS was observed following administration of the 45 μg target dose; enrollment to this cohort was discontinued, and additional step-up dosing may be implemented in the multi-dose regimens
  • No immune effector cell–associated neurotoxicity syndrome (ICANS) was observed

The poster will be available on the Resources & Publications section of the Company’s website following the presentation.

Cullinan Therapeutics Immunology Day on June 10 

Cullinan Therapeutics will host an Immunology Day on June 10. The event will showcase data for CLN-978 presented at the EULAR 2026 Congress, new data from the first RA multi-dose regimen cohort for CLN-978, anticipated next steps for CLN-978, and initial clinical data for velinotamig, a BCMAxCD3 T cell engager. Key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser will join Cullinan Therapeutics leaders to discuss the data and their clinical perspectives. Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations ([email protected]), or at the event registration page.  A webcast will be available via the events page of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.

About CLN-978 

CLN-978 is a novel, differentiated and highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers T cell-redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size (65 kDa), CLN-978 contains two single-chain variable fragments, one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody binding to human serum albumin to extend half-life. CLN-978 was developed by an internal Cullinan team and is a wholly owned asset. CLN-978 has the potential to offer a convenient, off-the-shelf, subcutaneously delivered therapeutic option for patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s disease.

About OUTRACE RA and OUTRACE SLE

OUTRACE RA and OUTRACE SLE are global Phase 1 studies of CLN-978 evaluating safety, as well as effects on disease activity and the immune system. Both studies are currently recruiting.

OUTRACE RA enrolls patients with active rheumatoid arthritis (DAS28-ESR ≥3.2) who have been treated with ≥2 prior targeted treatments and have evidence of B cell driven disease. Assessments include DAS28, synovial ultrasound, and optional synovial and lymph node biopsies.

OUTRACE SLE enrolls patients with active systemic lupus erythematosus (hSLEDAI ≥6) who have been treated with at least one biologic or immunosuppressive agent and are seropositive. Assessments include hSLEDAI, CLASI, and physician global assessment.

About Rheumatoid Arthritis (RA)

Rheumatoid arthritis is a chronic autoimmune disease primarily characterized by inflammation of the joints, which can lead to pain, swelling, stiffness, and permanent joint damage.1,2 The disease often affects multiple joints simultaneously, commonly the hands, wrists, and feet, but it can also involve other organ systems.2 Roughly 5.3 million adults live with rheumatoid arthritis across the U.S., France, Germany, Italy, Spain, the UK, Japan, and Australia, and the disease is more common in women than men.3-10 While disease-modifying antirheumatic drugs (DMARDs) have improved treatment outcomes, many patients continue to rely on chronic immunosuppression, have inadequate responses, experience disease flares, and face significant impairments in quality of life.11

About Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disease in which the immune system attacks a patient’s own tissues. The most common manifestations of SLE include skin rashes, arthritis, extreme fatigue, and low fevers. Lupus nephritis (LN) is a kidney disease and the most common severe manifestation of SLE. Approximately 40% of patients with SLE develop LN, which has a 10-year 30% mortality rate.12,13 The prevalence of SLE in the US is estimated at 160,000 to 320,000 cases and SLE affects approximately 3.4 million individuals globally.14,15 SLE is more prevalent in women and people of color. It occurs most often in people between the ages of 15 and 45 years but can occur in childhood or later in life as well. Currently available treatments can reduce the signs and symptoms of SLE; however, they do not routinely induce treatment-free remission, and most patients require lifelong immune suppression that treats symptoms without modifying the course of disease.

About Cullinan Therapeutics


Cullinan Therapeutics, Inc.
 (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: the efficacy and safety data from the Company’s ongoing Phase 1 OUTRACE RA and OUTRACE SLE clinical trials, our clinical development plan and anticipated development timeline for CLN-978, the clinical and therapeutic potential of CLN-978, the ability of clinical data from CLN-978 to help inform how therapies may be used in clinical practice, our plans regarding future data presentations, including for velinotamig, and other statements that are not historical facts. The clinical trials referenced in this press release are ongoing, and the data described are interim, subject to change, and based on data available as of a specified date. As patient enrollment continues and additional follow-up data is obtained, the reported safety profile and other clinical outcomes may change materially. There can be no assurance that the interim results will be predictive of final clinical trial results or that additional data will confirm or support these observations. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs, NDAs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will not be predictive of future results in connection with future studies or clinical trials; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts

Investors

Nick Smith
+1 401.241.3516
[email protected]

Media

Rose Weldon
+1 215.801.7644
[email protected]

References

  1. World Health Organization. (2023). Rheumatoid arthritis. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis
  2. Johns Hopkins Arthritis Center. Rheumatoid Arthritis Signs and Symptoms. https://www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ra-symptoms  
  3. Hunter, T. M., et al. (2017). Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatology International, 37(9), 1551–1557. https://doi.org/10.1007/s00296-017-3726-1
  4. Guillemin, F., et al. (2005). Prevalence of rheumatoid arthritis in France: 2001. Annals of the Rheumatic Diseases, 64(10), 1427–1430. https://doi.org/10.1136/ard.2004.029199 
  5. Steffen, A., et al. (2017). Epidemiologie der rheumatoiden Arthritis in Deutschland – eine Analyse anhand bundesweiter vertragsärztlicher Abrechnungsdaten. Zentralinstitut für kassenärztliche Versorgung in Deutschland, (17), 1–20. https://doi.org/10.20364/VA-17.08 
  6. Rossini, M., et al. (2014). Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatology International, 34(5), 659–664. https://doi.org/10.1007/s00296-014-2974-6 
  7. Fina-Aviles, F., et al. (2016). The descriptive epidemiology of rheumatoid arthritis in Catalonia: A retrospective study using routinely collected data. Clinical Rheumatology, 35(3), 751–757. https://doi.org/10.1007/s10067-014-2801-1 
  8. Abhishek, A., et al. (2017). Rheumatoid arthritis is getting less frequent: Results of a nationwide population-based cohort study. Rheumatology (United Kingdom), 56(5), 736–744. https://doi.org/10.1093/rheumatology/kew468 
  9. Kojima, M., et al. (2019). Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. Modern Rheumatology. Advance online publication. https://doi.org/10.1080/14397595.2019.1682776 
  10. Ackerman, I. N., et al. (2018). Projected burden of osteoarthritis and rheumatoid arthritis in Australia: A population-level analysis. Arthritis Care & Research, 70(6), 877–883. https://doi.org/10.1002/acr.23414 
  11. Radu, A. F., & Bungau, S. G. (2021). Management of rheumatoid arthritis: An overview. Cells, 10(11), 2857. https://doi.org/10.3390/cells10112857
  12. Mahajan, A. et al. (2020). Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus, 29(9), 1011–1020. https://doi.org/10.1177/0961203320932219
  13. Hocaoglu, M. et al. (2023). Incidence, prevalence, and mortality of lupus nephritis: A population-based study over four decades using the Lupus Midwest Network. Arthritis & Rheumatology, 75(4), 567–573. https://doi.org/10.1002/art.42375
  14. Tian, J. et al. (2022). Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351–356. https://doi.org/10.1136/ard-2022-223035
  15. Dall’Era, M. (2013). Chapter 21. Systemic lupus erythematosus. In J. B. Imboden, D. B. Hellmann, & J. H. Stone (Eds.), CURRENT Diagnosis & Treatment: Rheumatology (3rd ed.). McGraw-Hill. https://accessmedicine.mhmedical.com/content.aspx?aid=57272268  



Posted on

Roblox Investigation Initiated: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Roblox Corporation – RBLX

PR Newswire

NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Roblox Corporation (NYSE: RBLX). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit us at https://www.ksfcounsel.com/cases/nyse-rblx/ to learn more.

KSF

The investigation concerns whether Roblox and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.


>>>Click Here to Learn More.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/roblox-investigation-initiated-kahn-swick–foti-llc-investigates-claims-on-behalf-of-investors-of-roblox-corporation—rblx-302793156.html

SOURCE Kahn Swick & Foti, LLC

Posted on

SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

PR Newswire

NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until June 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against SES AI Corporation (NYSE: SES) (“SES” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 29, 2025 and March 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.

What You May Do

If you purchased securities of SES and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ses/?prs=prn to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 26, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

SES and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company overstated its business outlook by exaggerating the potential results of agreements with companies that had limited or no operational capacity; (ii) the company created the appearance of revenue by purchasing services tied to its own Molecular Universe transactions; (iii) despite its optimistic growth statements, SES AI faced significant logistics constraints in Q4 2025 that materially impacted revenue for that quarter; (iv) these issues raised serious doubts about SES AI’s 2026 growth prospects, which were later confirmed by weaker-than-expected revenue guidance for 2026; and (v) as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The case is Patel v. SES AI Corporation, et al., Case No. 26-cv-11894.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

KSF

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ses-ai-corporation-securities-fraud-class-action-result-of-weak-revenue-guidance-and-37-stock-decline—investors-may-contact-lewis-kahn-esq-at-kahn-swick–foti-llc-302793126.html

SOURCE Kahn Swick & Foti, LLC

Posted on

Sportradar Securities Fraud Class Action Result of Compliance Misrepresentations and 22% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

PR Newswire

NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until July 17, 2026 to file lead plaintiff applications in a securities class action lawsuit against Sportradar Group AG (NasdaqGS: SRAD) (“Sportradar” or the “Company”), if they purchased or otherwise acquired the Company’s Class A ordinary shares between November 7, 2024 and April 21, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

KSF

What You May Do

If you purchased shares of Sportradar as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-srad/?prs=prn to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 17, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

Sportradar and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company intentionally worked with black-market gambling operators to increase its revenues, despite its assurances of strict legal and regulatory compliance and claims that ethics and integrity were crucial for Sportradar’s operations; (ii) the Company’s Know-Your-Customer (“KYC”) and compliance processes were not as robust as Defendants’ had claimed; and (iii) as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The case is Smale v. Sportradar Group AG, et al., Case No. 26-cv-4112.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sportradar-securities-fraud-class-action-result-of-compliance-misrepresentations-and-22-stock-decline—investors-may-contact-lewis-kahn-esq-at-kahn-swick–foti-llc-302793134.html

SOURCE Kahn Swick & Foti, LLC

Posted on

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) — InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The units began trading on The Nasdaq Global Market (“Nasdaq”) under the ticker symbol “IPVVU” on June 4, 2026. Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable public warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “IPVV” and “IPVVW,” respectively.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. EarlyBirdCapital, Inc. acted as co-manager.

The public offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, New York, New York 10022, Attention: General Counsel, or by email at: [email protected]. 

A registration statement relating to the securities became effective on June 3, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About InterPrivate Investment Partners V, Inc.

InterPrivate Investment Partners V, Inc. is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company is controlled by affiliates of Ahmed M. Fattouh, Chairman and Chief Executive Officer, and is also led by Lex Sokolin, President; Brandon Bentley, General Counsel; Dimitri Goulandris and Nick Krenteras, Directors. The Company intends to leverage its management team’s broad experience and relationships across private equity, technology and digital assets to identify and consummate an initial business combination with a high-quality target business that can benefit from access to the public capital markets and from the experience, relationships and execution capabilities of its sponsor and management team. The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds from the offering. No assurance can be given that the net proceeds of the offering will be used as indicated, or that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

InterPrivate Investment Partners V, Inc.
Brandon Bentley
[email protected]
[email protected]
www.interprivate.com



Posted on

Command the Clone Wars’™ Most Cunning Operatives in Star Wars Zero Company™, LaunchingAugust 27

Command the Clone Wars’™ Most Cunning Operatives in Star Wars Zero Company™, LaunchingAugust 27

Watch the Official Gameplay Trailer Showcasing a New Take on Turn-Based Tactics Games; Pre-Orders Now Available for PC, PlayStation 5, Xbox Series X|S

REDWOOD CITY, Calif.–(BUSINESS WIRE)–
Electronic Arts Inc. (NASDAQ: EA) today announced that Star Wars Zero Company™, a single-player turn-based tactics game, developed by Bit Reactor in collaboration with Lucasfilm Games, will be available on PC, PlayStation® 5 and Xbox Series X|S starting August 27, 2026. Pre-Orders are now available on all platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605316929/en/

Star Wars Zero Company Key Art

Star Wars Zero Company Key Art

A new gameplay trailer delivers an action-packed look at the game’s gritty, cinematic take on turn-based tactics while previewing an original Star Wars™ story featuring new and returning Clone Wars characters.

Star Wars Zero Company’s visual storytelling and gameplay will immerse players in a tense, clandestine conflict taking place in the shadows of the Clone Wars. Players will step into the shoes of former Galactic Republic officer Hawks and current leader of Zero Company. Zero Company is an unconventional outfit of professionals for hire hailing from across the galaxy, including a Clone Trooper, a Mandalorian of the ancient Clan Verminoth, a Jedi Padawan and more. Together, Zero Company must hunt down and stop Kundri Fathom, leader of the Separatist-aligned cult, the Infinite Coil.

“Our team has poured everything we love about Star Wars into Zero Company,” said Greg Foertsch, CEO and Creative Director at Bit Reactor. “The bold characters, powerful storytelling, striking settings and the sense of heart beneath the battles in Star Wars has helped us create an experience that pushes the tactics genre forward by combining deep gameplay with cinematic elegance. We’ve worked hand-in-hand with Lucasfilm Games to create an authentic Star Wars story packed with unique new characters, robust character customization, a new ship, Separatist Droids and much more, all rooted in the conflict of The Clone Wars.”

“Star Wars Zero Company delivers an entirely new experience in the galaxy and for our fans,” said Douglas Reilly, VP and GM of Lucasfilm Games. “It pairs cinematic storytelling with strategic gameplay in a way that feels fresh for the franchise. Some of the most interesting stories come from new perspectives, and Zero Company explores the Clone Wars from deep within the shadows of the conflict, through a lens we haven’t seen before, while still feeling completely authentic to the world fans know.”

From Zero Company’s base of operations, The Den, players will recruit and progress skills of Operators, upgrade facilities, purchase new equipment and select their next mission from the holotable. On the battlefield, players will develop bonds between authored characters and player-created Operators, unlocking new support abilities, including cross-training benefits that improve their abilities and stats. Players will navigate an ever-changing galaxy map featuring more than 150 planets where each choice can change how their journey unfolds.

In Star Wars Zero Company customization is central to the experience. Hawks and recruited Operators can be created from eight iconic Star Wars species: Devaronian, Human, Neimoidian, Ovissian, Togruta, Twi’lek, Weequay and Zabrak. Voices, outfits and many other aspects of Hawks and an Operator’s appearance can be customized along with specializations and talents over time. It’s up to players to unite their Operators and form the best squad for the mission at hand.

Players can pre-order* Star Wars Zero Company Standard Edition for $49.99 SRP on PC and $59.99 SRP on PlayStation® 5 and Xbox Series X|S. The Deluxe Edition is available for $59.99 SRP on PC and $69.99 SRP on consoles and unlocks two additional unique cosmetic packs and five painted weapon themes inspired by the Clone Wars era. All pre-orders grant access to the Crystalline Astromech Cosmetic Pack, which includes an R3 droid, translucent “crystalline” astromech heads for the R4 and R5 droid variants, and the BR-1 droid, originating in Star Wars Zero Company. Deluxe Edition pre-orders include all pre-order bonus content in addition to the Deluxe Edition exclusive content.

Alongside the game’s launch, the soundtrack for Star Wars Zero Company, featuring an original score by GRAMMY® award-winning composer Gordy Haab, will be released August 27 via Walt Disney Records.

Follow EA Star Wars on X, Facebook, YouTube, and Instagram to stay up to date as more information is revealed.

PRESS ASSETS ARE AVAILABLE AT EAPressPortal.com

About Bit Reactor

Bit Reactor, LLC was created by longtime strategy game developers as an independent, developer-first game studio creating and perfecting experiences that blend game design, art and technology with a passion for making something great. The talented team is composed of some of the minds behind decorated titles like XCOM, Civilization, Gears of War, Elder Scrolls Online, and more. Follow Bit Reactor on X, Facebook, and Instagram for more.

About Electronic Arts

Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company develops and delivers games, content and online services for Internet-connected consoles, mobile devices and personal computers.

In fiscal year 2026, EA posted GAAP net revenue of approximately $7.5 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality brands such as EA SPORTS FC™, Battlefield™, Apex Legends™, The Sims™, EA SPORTS™ Madden NFL, EA SPORTS™ College Football, Need for Speed™, Dragon Age™, Titanfall™, Plants vs. Zombies™ and EA SPORTS F1 ®. More information about EA is available at www.ea.com/news.

EA, EA SPORTS, EA SPORTS FC, Battlefield, Need for Speed, Apex Legends, The Sims, Dragon Age, Titanfall, and Plants vs. Zombies are trademarks of Electronic Arts Inc. John Madden, NFL, and F1 are the property of their respective owners and used with permission.

Lucasfilm, the Lucasfilm logo, STAR WARS and related properties are trademarks and/or copyrights, in the United States and other countries, of Lucasfilm Ltd. and/or its affiliates. © & TM 2026 Lucasfilm Ltd. All rights reserved.

* Conditions and restrictions apply. See https://www.ea.com/games/starwars/zero-company/disclaimers for details.

Elizabeth Jackson

Global PR Manager

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Hardware Online Consumer Electronics Mobile Entertainment Technology Audio/Video General Entertainment Women Teens Men Film & Motion Pictures Electronic Games Software Entertainment Consumer

MEDIA:

Photo
Photo
Star Wars Zero Company Key Art
Logo
Logo